Nicastrin selects substrates for γ–secretase by turning away proteins with large ectodomains.
In dementia with Lewy bodies, basic scans are used in routine diagnosis. Multimodal imaging and new PET tracers for affected neurotransmitters of pathological deposits in the brain and gut are entering research settings.
At a DLB meeting, scientists reported progress in disentangling the notorious overlap in symptoms and pathology in this quintessential spectrum disease. (Hint: tangles are bad.)
Researchers will follow former football players at risk for the disorder to identify the best biomarkers and clinical criteria.
Studies find that a drug in cough syrup can improve symptoms, and that radiation therapy safely shuts off a salivary gland.
At the International Dementia with Lewy Bodies conference in Fort Lauderdale, Florida, fuzzy images of dying sympathetic cardiac nerve terminals proved to be a sharp aide to clinch this notoriously difficult diagnosis.
Dementia with Lewy Bodies: Is the Research Ready For Clinical Trials Through the Heart? Cardiology Tracer to Nail DLB Diagnosis Dementia with Lewy Bodies: Sharper Image for a Formerly Blurry Disease Brain Imaging: What Does it See in DLB? Lewy Pathology ...
At their international conference, DLB researchers demonstrated progress in defining a distinct identify for this Alzheimer’s-Parkinson’s overlap disease. This has helped prepare DLB for more therapeutics trials.
High expression of RNA-untranslated regions occurs in consistent patterns and seems to correlate with low protein expression, researchers report.
Gene and Stem Cell Therapies Make Strong Showing at ALS/MND Meeting Help for Speech, Swallowing, and Salivation Problems in ALS Does Free Radical Scavenger Edavarone Slow ALS? SOD1, Tau Swept Up in Prion-like Biology at ALS Meeting At the International ...
Trials of gene therapy for spinomuscular atrophy and stem cell treatments for ALS look promising.
A small set of biomarkers in CSF and plasma may predict progression to Alzheimer’s within three years.
Lawmakers have earmarked an additional $350 million for Alzheimer’s research, the largest increase in history.
Researchers detect liaisons between amyloid precursor protein and β-secretase in Golgi-derived vesicles and recycling endosomes, providing clues to where Aβ could form.
Computerized assessments and electroencephalography both hold promise for diagnosis and drug testing in Alzheimer’s disease, but the Food and Drug Administration does not yet know how to oversee the technology.